SENTANTE: Fully Robotic Peripheral Endovascular Interventions

NCT ID: NCT06537947

Last Updated: 2025-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-19

Study Completion Date

2024-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to evaluate the feasibility, safety and initial efficacy of the clinical and technical performance of the SENTANTE robotic system in the remote delivery and manipulation of commonly used and compatible guidewires and catheter-based devices for use in peripheral endovascular procedures.

The study will be a single-center, prospective investigation, designed to evaluate the safety, feasibility, and initial efficacy of robotic system for remote endovascular interventions in adults with disease which requires peripheral endovascular treatment with compatible devices. Participants meeting the inclusion criteria will undergo endovascular interventions using SENTANTE robotic system. Data will be collected through clinical assessments, imaging and other studies, laboratory tests, and feedback from medical personnel and patients.

The study will adhere to ethical guidelines, obtain informed consent from all participants, and be conducted under the oversight of the Clinical Events Committee.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Any Disease Which Requires Peripheral Endovascular Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Endovascular interventions

Group Type EXPERIMENTAL

Endovascular intervention using the SENTANTE endovascular robotic system

Intervention Type PROCEDURE

1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.
2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.
3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endovascular intervention using the SENTANTE endovascular robotic system

1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.
2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.
3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is ≥ 19 years and ≤ 90 years of age.
* Subject is willing and able to provide appropriate study-specific informed consent and follow Clinical Investigation Plan (CIP) procedures.
* Life expectancy ≥ 12 months from the date of the index procedure.
* Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
* Subject is diagnosed with a disease which requires peripheral endovascular intervention using compatible with SENTANTE guidewires and catheter-based devices.

Exclusion Criteria

* Planned interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index procedure.
* Subjects with myocardial infarct or cerebrovascular event within 3 months prior to index procedure.
* Severe vascular anatomy that would preclude safe sheath insertion, or deliverability of stent.
* History of bleeding diathesis or coagulopathy.
* History of thrombophilia.
* Sensitivity to contrast media that cannot be adequately pre-treated.
* Sensitivity to both forms of CIP-acceptable anticoagulation strategies (i.e., both heparin AND Bivalirudin).
* Sensitivity to an antiplatelet agent AND all CIP acceptable alternative antiplatelet options.
* Major neurologic deficit with NIHSS of ≥ 15.
* Clinical condition that, in the opinion of the investigator, makes endovascular therapy impossible or hazardous.
* Subject previously enrolled in this clinical trial.
* Possible / probable non-compliance of subject with CIP required follow up or medication.
* Subject is currently participating in another clinical trial that has not completed its primary endpoint assessment or would confound this Clinical Study.
* Signs of SARS-CoV2 (COVID-19) active infection.
* Patients with intervention-related anxiety, separation anxiety, autophobia and individuals that cannot be left alone without additional sedation or close supervision.
Minimum Eligible Age

19 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KCRI

OTHER

Sponsor Role collaborator

SIA Kotello

UNKNOWN

Sponsor Role collaborator

Syntropic Corelab

UNKNOWN

Sponsor Role collaborator

Inovatyvi Medicina UAB

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dainis Krievins, Prof PhD MD

Role: PRINCIPAL_INVESTIGATOR

Pauls Stradins Clinical University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pauls Stradins Clinical university hospital

Riga, , Latvia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Latvia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIV-24-05-047118

Identifier Type: OTHER

Identifier Source: secondary_id

24-SEN-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RevCore for In Stent Thrombosis
NCT06394739 RECRUITING
The SENTRY Clinical Study
NCT01975090 COMPLETED NA